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Purpose.Prospective analysisofthe eﬃcacy of the originalprotocol SPbHL-05 was performed. PatientsandMethods.Sixtypatients
with Hodgkin’s lymphoma (HL) aged less than 18 years old were treated in accordance with SPbHL-05 from January 2000, to July
2009. In induction chemotherapy we used VBVP and ABVD schedules followed by involved-ﬁeld radiotherapy. Fourteen patients
(23,3%) with 0–2 adverse factors (the favourable group) received two cycles of chemotherapy (VBVP), 25 children (41,7%) with
3-4 unfavorablesigns(the intermediate group) received twocycles ofVBVPalternating with twocycles ofABVD, 21 patient (35%)
who had5 ormoreadverse prognostic factors (theunfavourablegroup) received three cycles of VBVPalternating with three cycles
of ABVD. Results. With a median follow-up of 68 months, overall survival (OS) at 5 years is 91.3%, event-free survival (EFS)
is 82.8%. OS in the favourable and intermediate risk group were 100%, EFS were 92,9% and 90,7%, respectively, OS and EFS
in unfavourable risk group—77,1% and 55,6%, respectively. Conclusion. The identiﬁcation of prognostic risk factors and using
medicines with less prominent side eﬀects would be of major importance in the development of new strategies of treatment for
childhood HL.
1.Introduction
Childhood Hodgkin’s lymphoma is curable disease with sur-
vival rate more than 90%. It has become after the introduc-
tion of chemotherapy [1–4] and new radiation regimen [5–
7]. But with increasing cure rates of mostly patients, late
toxicities have been reported among survivors. The long-
term frequency of cardiopulmonary, gonadal, and neoplastic
treatment complications has been alarming after MOPP,
MOPP-like schedules, and irradiation. In addition, subtotal
nodal irradiation leads to an increased frequency of sec-
ond malignancies (solid tumor and leukemia). The relative
r i s ko ft h el a t ee ﬀects is estimated as ranging from 2 to 6
[8, 9].
Modern current therapy uses risk-adapted and risk-re-
sponded chemotherapy with restricted doses of alkylating
agents, anthracyclines, and bleomycin and low-dose, in-
volved-ﬁeld (node-ﬁeld) radiotherapy, with the identiﬁca-
tion of additional clinical and biologicrisk factors in attempt
to avoid treatment-associated toxicity while maintaining
high cure outcomes. Recent study results demonstrate that
patients with favourable disease are excellent candidates for
therapy reduction.
The optimal therapy program for patients with HL goes
on to be discussed, and this study is representative of the
original risk-adapted protocol SPbHL-05 for therapy of the
similar patients with the dual goals of reducing late adverse
treatment eﬀects while sustaining eﬃcacy.
2.Materialand Methods
2.1. Eligibility Criteria. Between January 2000 and July 2009,
previously untreated 60 patients less than 18 years old
who had biopsy-proven HL were eligible. All patients were
required to have clinical stage according to the modiﬁed
Ann Arbor criteria [10, 11]. The clinical staging evalua-
tion included medical history and physical examination,
complete blood count, urinalysis, erythrocyte sedimentation2 Journal of Oncology
rate, blood chemistry, chest X-ray, abdominal ultrasound,
thoracic and abdominal computed tomography scan with
contrast, bone marrow biopsy, and isotopic bone marrow,
spleen, liver, and bone scans. Gallium scan was used to
monitor response if need were.
2.2. ProtocolDesign (SPbHL-05)
2.2.1. Primary Chemotherapy. In induction chemotherapy,
we used VBVP (vinblastine, bleomycin, etoposide, and pred-
nisone) and ABVD (adriamycin, bleomycin, vinblastine, and
dacarbazine) schedules followed by consolidating radiother-
apy. VBVP was administered as follows: vinblastine 6mg/m2
intravenously (IV) on days 1 and 8, bleomycin 10mg/m2 IV
on day 1, etoposide 100mg/m2 IV on days 1 through 5, and
prednisone 40mg/m2 orally on days 1 through 8 [12].
We introduced the six-factor prognostic scoring system
thathasbeenpreviouslyreported[13].Itgivesapossibilityto
selectpatientsonfavourable,intermediate,andunfavourable
risk groups. In the calculation of the prognostic index (PI),
several unfavorable factors are taken into account: the age
of 10 years or more, 4 or more lymphatic zones involved,
“peripheral bulky disease” when any nodal mass more
than 5cm in diameter or/and “mediastinal bulky disease”
when the ratio of the largest transverse diameter of the
mass to the transverse diameter of the thorax was at least
0,33, biological “b” stage that was deﬁned by two or more
of the following ﬁndings: erythrocyte sedimentation ratio
≥30mm/h, ﬁbrinogen ≥0,4g/dL, serum albumin ≤4g/dL,
leukocytes ≥12 × 103/mm3,a n dα2-globulin ≥ 12% of
whole globulin count, systemic “B” symptoms (fever, night
sweats, or a weight loss of >10% of the normal body weight),
and stage IV disease [13]. These factors incorporated into
t h eP Iw h i c hw a sd e ﬁ n e da st h en u m b e ro fa d v e r s ef a c t o r s
present at diagnosis. Children were subdivided into 3
groups based on risk stratiﬁcation. Patients with PI = 0–
2 (favourable risk group) received two VBVP, children
with PI = 3-4 (intermediate risk group) were treated with
two cycles of VBVP alternating with two cycles of ABVD,
and patients with PI = 5-6 (unfavourable risk group)
were treated with three cycles of VBVP alternating with
three cycles of ABVD. VBVP were repeated every 3 weeks
and ABVD repeated every 4 weeks as permitted by count
recovery.
2.2.2.Radiotherapy (RT). Externalbeamradiation wasdeliv-
ered with megavoltage equipment—either a telecobalt or a
linear accelerator. Patients who achieved complete response
or75%orgreaterreductionsinalldiseasemanifestationwere
administered 25Gy. RT began 2 weeks after the completion
of chemotherapy and was given in 1,8Gy fractions, ﬁve
times per week. Patients who did not reach these status were
administered 36Gy in 20 fractions during 4 weeks.
Inall patients,theﬁelds werelimitedtotheinvolvedsites,
as deﬁned by the initial clinical and radiologic examination
(involved-ﬁeld irradiation—IFI). Irradiation of adjacent
areas was not performed.
The treatment design is shown in Figure 1.
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Figure 1: Design of the study.
This trial was approved by the Ethics Committee at the
N.N. Petrov Research Institute of Oncology. Written in-
formed consent of parents was required before therapy.
2.3. Response Criteria and Followup. Patients were evaluated
for response after two, four, and six cycles in the chemother-
apy arms and after completion of RT.All initial involved sites
h a dt ob em e a s u r e da n dd o c u m e n t e d .
A CR was deﬁned as the disappearance of any clinical
and radiological evidence of active disease over a period of
4 weeks.
A partial remission (PR) was deﬁned as a 50% or greater
reduction in all disease manifestation compared with the
initial involvement for at least 4 weeks.
Progressive disease was deﬁned as enlargement of mea-
surable tumors by more than 25% or appearance of any new
lesions.
Stabledisease was not satisfying the deﬁnition of CR, PR,
or disease progression/relapse.
Restaging was performed 2 weeks after the end of chem-
otherapy and 4 weeks after the end of irradiation. Restaging
consistedofacontrolanddocumentationofall initialdisease
manifestation by clinical methods including a physical ex-
amination, complete blood count, urinalysis, erythrocyteJournal of Oncology 3
sedimentation rate, blood chemistry, chest X-ray, and ab-
dominal ultrasound, computed tomography of the chest and
abdomen.A bonemarrow biopsyand isotopicbone marrow,
spleen, liver, and bone scans were repeated if the initial
examination detected a disease manifestation.
Follow-up examination including medical history and
physical examination, complete blood count and blood
chemistry, chest X-ray, and abdominal ultrasound were per-
formed within the ﬁrst 2 years in 3-month interval, at years
3–5 in 6-month interval, and from year 5 once a year.
2.4. Statistical Analysis. OS was deﬁned as the time from be-
ginning of treatment to death, whether disease-related or
not, or last follow-up examination.
EFS was deﬁned as the time from beginning of treatment
to an adverse event (relapse, disease progression, death in
remission, and second malignancy) or last follow-up exami-
nation.
OS, EFS and standard errors (SE) were estimated by the
methods of Kaplan and Meier [14]. Test of statistical signif-
icance in the comparison of survival curves were calculated
using the log-rank test. Analysis was carried out using Statis-
tica, version 6.
2.5. Dose Intensity. Actualtreatment duration was calculated
as a time between the ﬁrst and ﬁnal cytotoxic drug adminis-
tration plus 14 days, representing the theoretical duration of
last treatment cycle. The total actual dose given represented
the sum of all administered doses per square meter of body.
Dose intensity was calculated by dividing the total actual
dose in milligrams by total actual duration in days and
subsequently expressed as the percentage of initially planned
theoretical dose intensity [15].
3.Results
3.1.PatientCharacteristics. Sixtychildren wereenrolled onto
the trial. The demographic and clinical characteristics of the
study population are listed in Table 1.
The male-female ratio was 1:1,3. The median age was 14
years, with a range of 4 to 18. Six of the 60 (10%) were less
than 9 years, 54 (90%) were 10 years of age or older.
Twenty eight had stage III and IV disease, while 32 had
stage I and II disease.
Twenty-three of 60 patients (38.3%) presented systemic
symptoms. Biological “b” stage was diagnosed in 37 patients
(61.7%).
Histological subtypes were lymphocyte predominance
in 2 cases (3.3%), nodular sclerosis in 46 (76.7%), and
mixed cellularity in 9 (15%); three cases (5%) were not
subclassiﬁed. Thus, in the series about 90% had either
nodular sclerosis or mixed cellularity, while only 3.3% had
lymphocyte predominance.
Twenty threepatients(38.3%)hadone,two,orthreesites
oflymphnodeinvolvement,whereas37patients(61.7%)had
four or more sites of node involvement.
Thirty three patients (55%) had “bulky” disease.
Table 1: Demographic and clinical characteristics.
Characteristics No. of patients %
Age
<9y e a r s 6 1 0
≥10 years 54 90
Sex
Male 26 43.3
Female 34 56.7
Stage
I3 5
II 29 48.3
III 13 21.7
IV 15 25
B-symptoms
Present 23 38.3
Absent 37 61.7
Biological“b” stage
Present 37 61.7
Absent 23 38.3
Histology
Lymphocyte predominance 2 3.3
Nodular sclerosis 46 76.7
Mixed cellularity 9 15
Not subclassiﬁed 3 5
Involved nodal sites
1–3 23 38.3
≥4 37 61.7
“Bulky” disease
Absent 27 45
Present 33 55
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Figure 2: Distribution of risk groups.
The distribution of prognostic groups, expressed as the
PI, is listed in Figure 2.
Fourteen patients (23.3%) had none, one, or two adverse
factors (favourable risk group). Twenty ﬁve patients (41.7%)
had three or four adverse factors (intermediate risk group).
Twenty one children (35%) had ﬁve or six adverse factors
(unfavourable risk group).4 Journal of Oncology
Table 2: 5-years OS and EFS according to patient risk groups.
Survival, % Favourable
risk group
Intermediate
risk group
Unfavourable
risk group
OS 100 100 77.1
EFS 92.9 90.7 55.6
0123456789 1 0
(years)
65
70
75
80
85
90
95
100
(
%
)
OS 91.3 SE 3.7
EFS 82.8 SE 5
Figure 3: Results of treatment.
3.2. Treatment Outcomes. A f t e rt h e r a p y ,5 7( 9 5 % )o f6 0p a -
tients entered CR. One child had stable disease, and one
patient developed progressive disease after ﬁve cycles of
chemotherapy. A cause of death after ﬁve cycles in one case
was the accompanying intercurrent viral epiglottitis.
With a median followup of 68 months (range 7 to 115
months), the 5-year OS is 91.3% (SE 3.7%), and the EFS is
82.8% (SE 5.0%) (Figure 3).
No patients have been lost to follow up.
Of the 57 patients who received the protocol and
achieved CR, 9 (15.8%) relapsed at a median time of 50
months from initial diagnosis (range, 6 to 104 months):
seven relapsed patients initially were treated according to
principles for unfavourable risk group, two others relapsed
patients were treated according to principles for favourable
and intermediate risk groups.
According to the risk group division, 5-year OS in the
favourable and intermediate risk group were 100%, EFS
were 92.9% and 90.7%, respectively, and OS and EFS in
unfavourablerisk group were 77.1% and 55.6%, respectively,
(Table 2).
No patients developed second malignancies.
3.3.Administration ofTherapy. Overall,twopatientsreceived
fewercycles.Thereasons forearlyterminationofchemother-
apy were progressive disease and death from viral infec-
tion.
Decreasing dose-time intensity of schedules ≤25% was
not signiﬁcantly inﬂuences the outcomes (Figure 4).
50
60
70
80
90
100
(
%
)
012345678 1 0
(years)
9
76%∗ 91.7 SE 4.6
<
<75% 5%∗ 90.7 SE 6.3
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Figure 4: OS according to dose-time intensity of schedule (P =
.87941).
3.4. Toxicity. Treatment was well tolerated and without sig-
niﬁcant toxicity. Table 3 lists the acute toxicities associated
witheachchemotherapy regimenduring thetime thepatient
was on treatment.
The number cycles was administered to 254 (185 VBVP
and 69 ABVD).
Nausea and vomiting were mild because of premedica-
tion with antiemetic drugs. Oral mucositis occurred in 2.8%
of the cycles. Leukopenia and neutropenia were the most
common haematologic toxicity with grade 1-2 in 13.8% and
12.5%,respectively, grade3-4in6.2%and4.4%,respectively,
of the cycles. Grades 2, 3, or 4 thrombocytopenia were never
recorded. Anemia was rare, with grade 1-2 in 8.6% of the
cycles.
4.Discussion
Hodgkin’s lymphoma has one of the best cure rates of all
of childhood and adolescent malignancies. Consequently,
ongoing studies aim at reducing treatment-related toxicity,
including second tumors such as acute myeloid leukemia,
non-Hodgkin’s lymphoma, and solid tumors. Using the
modern combination regimen, risk-adapted therapy models
might be warrant the excellent cure rates of patients with
HL and should help avoid overtreatment and reduce life-
threatening toxicity in patients.
German-Austrian Hodgkin’s disease study (DAL-HD)
worked out the well-known risk-adapted treatment for HL
[16]. The study was designed to reduce, step-by-step, loads
of the treatment in low and intermediate risk group. High-
dose and extended-ﬁeld irradiation were limited to involved-
ﬁeld irradiation at a dose of 20–25Gy (DAL-HD 90). They
omitted procarbazine in boys as a cytotoxic agent causing
testicular damage.Journal of Oncology 5
Table 3: Toxicity.
Toxicity Grade 1 Grade 2 Grade 3 Grade 4
No. of cycles (%) No. of cycles (%) No. of cycles (%) No. of cycles (%)
Nausea, vomiting 49 (19.3) 64 (25.2) 2 (0.8) —
Oral mucositis 7 (2.8) — — —
Leukopenia 15 (5.9) 20 (7.9) 8 (3.1) 8 (3.1)
Neutropenia 24 (9.4) 8 (3.1) 7 (2.2) 7 (2.2)
Thrombocytopenia 2 (0.8) — — —
Anemia 12 (4.7) 10 (3.9) — —
Hepatic toxicity 29 (11.4) 12 (4.7) 5 (2) 1 (0.4)
Combined modality therapy schedule of the DAL-HD
study included induction chemotherapy (OPPA/OEPA and
COPP regimens) followed by radiotherapy. Stratiﬁcation
randomization method was used. Variables were selected
according to the stage of the disease and systemic “B” symp-
toms. After stratiﬁcation, similar strata were randomly
assigned to treatment group TG1 (early stages), TG2 (inter-
mediate stages), and TG3 (advanced stages). Patients with
stage IA,IB,and IIA(TG1)received twocycles;children with
stages IIB and IIIA (TG2) received four cycles; remaining
patients with stages IIIB and IV (TG3) received six cycles.
Radiotherapy was administered to the initially involved
areas. The total dose was 25Gy in TG1 and TG2 and 20Gy in
TG3. A boost up to 35Gy total dose was given to sites with
residual lymphoma.
Eighty-three patients were treated using combined
modality therapy schedule of the DAL-HD study (versions
87 and 90) between June, 1987 and February, 2000 in our
clinic [17]. The median follow-up duration was 116 months
(range,8to 255months). Seventy-twoper cent ofall patients
received only two or four cycles; 28% received six cycles.
OS of5 years after diagnosis was 93.3%, whereas in DAL-
HDstudy,it was98% [16];as toEFS,itcame to79.9%versus
86%, respectively. According to risk group division, OS in
TG1was100%inbothDAL-HDstudyandourinvestigation.
In TG2, the contributions were 100% and 96.7%, and in
TG3 they were 98% and 87%, respectively. As for EFS, the
values in TG1 were 94% in DAL-HD study and 84.4% in
our investigation. In TG2, the contributions were 91% and
81.4%, and in TG3, they were 93% and 72.7%, respectively.
There were fewer patients in TG1 (32.5% in the study and
48% in DAL-HD study) and more patients in TG2 (39.8%
and 22.2%, resp.). The number of patients in TG3 was
approximately identical (27.7% and 29.9%, resp.).
The proportion of the second tumors did not coincide in
the studies, being 0.9% [18] and 3.6%, respectively. We do
not exclude further detection of second neoplasms because
of the higher doses of alkylating agents and anthracyclines in
TG2 and TG3.
Overall, it may be conclude that the therapy regimen of
the DAL-HD study represented a risk-adapted treatment
with high eﬃc a c y .B u tt h ep r o t o c o lh a dt w od i s a d v a n t a g e s .
On the one hand, alkylating agents and anthracyclines
causing late adverse sequels included in chemotherapy reg-
imen of the DAL-HD study. The cumulative total dose of
cyclophosphamide and procarbazine were 2000mg/m2 and
6000mg/m2 in TG3, respectively, and the total dose of dox-
orubicin was 80mg/m2 that were analogous to three cycles
MOPP or COPP or ABVD.
On the other hand, in DAL-HD study patients were
selected according only two parameters: stage of the disease
and “B” symptoms.
For these reasons, the new program SPbHL-05 has been
oﬀered. Our protocol of risk-adapted therapy was extremely
eﬀective for disease control in patients from favourable
and intermediate risk groups, but treatment results in
unfavourablerisk grouphavebeenlessimpressive.Treatment
of children from unfavourable risk group resulted in inferior
event-free and overall survival. OS in the favourable, inter-
mediate and unfavourable risk group were 100%, 100%, and
77.1%, and EFS were 92.9%, 90.7%, and 55.6%, respectively;
OS were 100%, 100% and 77.1%, respectively. Our experi-
ence with protocol decreasing cumulative doses of alkylating
agent and anthracyclines in combination low-dose involved-
ﬁeld radiotherapy showed excellent outcomes.
Thefollowing majorﬁndings emergedfromtrial SPbHL-
05. (1) Treatment was well tolerated and without signiﬁ-
cant hematological and gastrointestinal toxicity. (2) With a
median followup of 68 months (range 7 to 115 months), the
5-year OS for all patients was 92.7% (SE 3.6%), and EFS
was 79.6% (SE 5.6%). (3) The study showed signiﬁcantly
improved complete remission rate, event-free survival, and
overall survival for VBVP (in favourable risk group) or
the sequential VBVP-ABVD (in intermediate risk group)
followed by radiotherapy. The rates achievedon theprogram
were comparable to other series. Although the followup was
short and only 5-year result was available, there were no
diﬀerences in survival rates between programs (for example,
DAL-HD).(4)Nopatientsdevelopedsecondmalignanciesin
our series, while 3 cases of second neoplasms occurred after
the DAL-HD. While adequate for the purpose of examining
the regimen, the median followup of approximately 5
years interrupted a more detailed comparison of the risk
of second malignancy between two programs. (5) Using
VBVP chemotherapy excluded alkylating agent and anthra-
cyclines. (6) Low-cumulative doses of potentially dangerous
medicines were reached by using sequential VBVP-ABVD.
(7) Own prognostic index included 6 adverse prognostic
factors (in DAL-HD risk groups were selected according only
to the stage of the disease and systemic “B” symptoms).6 Journal of Oncology
These results suggest that it is feasible to reduction alky-
lating agent and anthracyclines in children with Hodgkin’s
lymphoma, but this approach results in inferior disease
control in those from unfavourable risk group. Stratiﬁcation
of patients on risk group according to own prognostic
index is feasible and proven to be eﬀective, but additional
stratiﬁcation is required in unfavourable risk group. Maybe
stratiﬁcation according to the prognostic score by D. Hasen-
cleverand V. Diehl is needed in this group [19].
Based on our results, it may be reﬂected that the SPbHL-
05 represents an eﬀectiverisk-adapted and response-adapted
treatment strategy forHodgkin’s lymphoma forchildren and
adolescents.
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